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Desde o meu primeiro contacto com a Cirurgia, no quarto ano deste curso que agora 
termino, que esta foi uma das áreas que mais interesse despertou em mim. Isto foi sobretudo 
devido ao Prof. Gil Faria e ao modo como ensinava a sua turma, como focava as suas aulas 
nos aspetos práticos da disciplina, como se mostrava disponível para os seus alunos e como 
conseguia tornar a Cirurgia algo cativante e em que efetivamente, tinha gosto em estudar e 
saber mais.  
Daí surgiu o interesse em escrever a minha tese nesta área. Inicialmente ponderei 
escrever um artigo de investigação. No entanto, uma vez que estive ausente do país durante 
uma grande parte do ano letivo, conclui que tal me impediria de fazer uma investigação como 
desejaria, no hospital e com os doentes, pelo que acabei por decidir realizar uma revisão 
bibliográfica.  
As possibilidades que a Cirurgia pode oferecer aos doentes oncológicos, por um lado 
pelo eventual alongamento da sua vida, por outro pelo alívio de sintomas altamente 
debilitantes e incapacitantes, sempre me cativou a atenção. Consequentemente, este tema, 
sugerido pelo meu tutor de tese, pareceu-me apropriado.  
Apesar de alguns obstáculos na elaboração desta revisão e de constantemente ter de 
conciliar o extensivo estudo que o 6º ano exige com este trabalho, consegui realizá-lo e estou 
satisfeito com o resultado final. Aproveito para agradecer ao Prof. Gil Faria a sua constante 
disponibilidade e motivação desde o inicio deste trabalho. 
É com nostalgia que termino este precurso de seis anos, e com entusiasmo que 
aguardo o meu futuro na Medicina. 
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Resumo 
Introdução: O cancro gástrico é uma das principais causas de morte por neoplasia em 
Portugal e no mundo. Frequentemente o cancro gástrico é diagnosticado numa fase 
disseminada (estadio IV). Este grupo de doentes tem um prognóstico muito reservado, sendo 
que a vantagem da gastrectomia paliativa ainda não está determinada.  
Objetivos: Esta revisão sistemática tem por objetivo sumarizar a literatura atualmente 
existente relativamente a intervenções cirúrgicas em doentes com cancro gástrico metastizado.  
Material e Métodos: Através da base de dados PubMed foram selecionadas 
publicações que analisaram eventuais benefícios da gastrectomia paliativa, em doentes com 
cancro gástrico em estadio IV, a nível de sobrevida, paliação de sintomas e impacto na 
qualidade de vida.  
Resultados: Na maioria das publicações, a sobrevida após gastrectomia paliativa foi 
avaliada pelo tempo de sobrevida mediano (7.5-13.25 meses). Foi observado um benefício 
estatisticamente significativo neste parâmetro e nas taxas de sobrevida a 1, 2 e 3 anos na 
maior parte dos estudos, sem diminuição da qualidade de vida do doente. Verificou-se 
também um impacto positivo desta intervenção na sintomatologia. A quimioterapia paliativa 
pós-operatória é um fator prognóstico importante. A gastrectomia paliativa foi associada a 
maior taxa de morbilidade pós-operatória (13-23.9%) e a menor taxa de mortalidade pós 
operatória (0-4.1%).  
Conclusão: A gastrectomia paliativa tem impacto significativo na sobrevida dos 
doentes com cancro gástrico em estadio IV. No entanto, a literatura atual tem limitações 
importantes, pelo que a evidência científica deve ser interpretada com cautela, tendo em conta 
as eventuais consequências para a qualidade de vida deste grupo de doentes. Deste modo, são 
necessários estudos clínicos randomizados para melhor caracterizar o potencial benefício 
deste procedimento. 
 
Palavras-chave: Cancro gástrico avançado, Mestástase, Gastrectomia Paliativa, 
Resseção gástrica, Sobrevida, Qualidade de Vida  
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Abstract 
Introduction: Gastric cancer is one of the leading causes of cancer death in Portugal 
and in the world.  In many patients it is diagnosed at an advanced (stage IV), which conveys a 
poor prognosis. The benefit of palliative gastrectomy in this setting is yet unclear, especially 
considering that other palliative interventions are available for these patients.  
Aim: In this review we intend to summarize the existing literature reporting on 
surgical interventions for patients with metastasized gastric cancer. 
Methods: A search for the literature was performed using the PubMed database where 
clinical studies investigating palliative gastrectomy in stage IV (M1) gastric cancer patients 
were selected. An analysis of survival, symptom palliation and quality of life outcomes was 
then performed. 
Results: Survival in patients undergoing palliative gastrectomy was usually reported 
through median survival time (MST), ranging between 7.5 and 13.25 months. A statistically 
significant benefit on MST and/or 1, 2, and 3-year survival with palliative gastrectomy was 
reported in most publications. A positive impact with palliative gastrectomy on symptom 
relief was observed. This benefit can be achieved without significantly impairing patient’s 
quality of life. Post-operative chemotherapy is an important prognostic factor. A higher post-
operative mortality (0-4.1%) and lower post-operative morbidity (13-23.9%) were observed 
with palliative gastrectomy. 
Conclusion: Palliative gastrectomy seems to have a significant impact in the survival 
of stage IV gastric cancer patients. However, due to important limitations in current literature, 
this evidence should be interpreted cautiously, especially when considering the eventual 
consequences of the intervention in the patients’ quality of life. Hence, adequately designed 
randomized trials are required to assess the global benefit of this surgical procedure.  
 
Key-words: Advanced Gastric Cancer, Metastasis, Palliative Gastrectomy, Gastric 
Resection, Survival, Quality-of-Life 
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Introduction 
Gastric cancer was the fourth most common malignancy and the third leading cause of 
cancer death in men and the fifth leading cause in women in the world in 2008.
1
 There are 
significant regional disparities in epidemiology and patient survival.  In Portugal’s National 
Program for Oncologic Diseases 2013 Report, gastric cancer had an age standardized 
incidence of 19.6 cases per 100 000 inhabitants in 2007 and an age standardized mortality rate 
of 14.4 deaths per 100 000 inhabitants in 2011, with values increasing over the previous 
years.
2
 These numbers are significantly higher compared respectively with the 13.7 and 10.3 
age standardized incidence and mortality rates reported in 2012 in Europe.
3
 
The symptoms of gastric cancer  are  generally  nonspecific (including epigastric pain, 
early satiety, and weight loss) and contribute frequently to its advanced stage at diagnosis.
4
 
According to SEER (Surveillance and End Results) database in 31 % of gastric cancer cases, 
the tumor has already directly spread outside the stomach or to the regional lymph nodes and 
in 34%, the tumor has metastasized to distant organs.
5
 The prognosis of advanced gastric 
carcinoma is very poor, with overall survival of 3–5 months with best supportive care.6  
Patients  with  advanced  disease  can  develop  complications such as bleeding, 
perforation and obstruction; and symptoms related to malnutrition, such as anorexia, cachexia 
and weight loss.
4
 Interventions for palliation of symptoms include chemotherapy, 
radiotherapy, complete or partial gastrectomy, surgical bypass, and endoscopic options (e.g., 
stent placement, cauterization, gastrostomy tubes). However, interventions undertaken to 
relieve major symptoms may result in prolongation of life.
7
 
In this setting, it is yet unclear how beneficial gastrectomy might be compared to other 
procedures available for the treatment of advanced, stage IV gastric cancer patients.  A 
systematic literature review of quality of life (QoL), symptom palliation and overall survival 
(OS) outcomes was therefore executed. Our objective was to summarize the existing literature 
reporting on surgical interventions for patients with metastasized gastric cancer. 
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Materials and Methods 
A search for the literature published between January 2005 and March 2015 was 
performed using the PubMed database. The search key terms were “stomach cancer”, “gastric 
cancer”, “palliative gastrectomy” and “palliative resection”. 
Any prospective or retrospective clinical studies evaluating outcomes related to 
palliative gastrectomy or comparing it with other interventions in stage IV gastric cancer 
patients were considered.  
Advanced gastric cancer (stage IV) is defined by both the JGCA Gastric Carcinoma 
Classification 3
rd
 editon and AJCC Cancer Staging Manual 7
th
 edition as any T, any N and 
M1, according to the TNM staging system.
8,9
 However, studies conducted before the AJCC 
7
th
 edition publication (in 2010) would classify as stage IV gastric cancer, according to its 
previous edition, not only M1 patients but also T4, N1 – 3 M0 and T1 – 4 N3 M0 patients. 
Thus, any studies using the AJCC Cancer Staging Manual 6
th
 edition were excluded, unless its 
data presentation allowed for the retrieval of data exclusive to M1 patients. 
The terms non-curative, palliative and reduction surgery are frequently used 
interchangeably and often mentioned without clarification on their actual intent. Both NCCN 
and JGCA Gastric Cancer Guidelines are clear that palliative gastrectomy should be defined 
as a surgical intervention whose primary intention is the relief of symptoms, even though it 
might prolong the patient’s survival.7,10 Hence it is not possible to palliate in the absence of 
symptoms and any data corresponding to patients submitted to gastrectomy with clear 
“curative” or “reduction” intent or clearly selected for being symptom free was not used in 
this review. 
Data referring to patients who had other interventions prior to palliative gastrectomy, 
including previous surgery, neoadjuvant chemotherapy, radiation therapy or a combination of 
these was excluded. 
Animal studies, case reports or articles not published in English were not included. 
The title and abstract of the publications obtained through the initial search were 
screened for their potential eligibility. The potentially eligible papers were extracted and full 
text reviewed, and the studies to be included in this review selected according to the criteria 
aforementioned. Additional articles corresponding to other relevant investigations were drawn 
from the reference list of these publications and included if meeting the same criteria. 
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The main data retrieved from these selected studies were outcomes reporting on 
overall survival, postoperative mortality and morbidity rates, postoperative palliation of 
symptoms and postoperative quality of life measures (standardized or not).  
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Results 
The initial search identified 902 articles, 81 of which were included after screening of 
titles and/or abstracts. After full text-review, according to the criteria mentioned above 21 
were finally included in the review. Another 2 articles drawn from the reference list of these 
publications were included. All 23 included articles were observational retrospective trials. 
No randomized controlled trials were found.  
Survival benefit after palliative gastrectomy 
We identified eight studies reporting survival data for palliative gastrectomy in M1 
patients, without specifying metastasis location (Table 1). In most of the studies, post-
operative chemotherapy was performed in most patients. Survival was usually reported by 
median survival time (MST), ranging between 7.5 and 13.25 months. Two studies
11,12
 
reported 1, 3 and 5 year survival rates, ranging between 37.7%-49.1%, 16.7%-20.8% and 5%-
11.2% respectively.  
Four studies compared palliative gastrectomy with non-resection approaches. A 
statistically significant benefit (p<0.05) on MST with palliative gastrectomy was found in 
three of them. One of these studies also reported that among non-resected patients, the type of 
surgical intervention had no influence on their prognosis. 13 A fourth study14 however, failed 
to show the same benefit for palliative gastrectomy. This investigation, specifically aimed at 
comparing self-expanding metallic stent with palliative gastrectomy (both followed by 
palliative chemotherapy) for pyloric stenosis, reported a longer MST when a non-resection 
approach was taken, even though this difference was not statistically significant (p=0.671). 
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Table 1. Survival of patients undergoing palliative gastrectomy for stage IV gastric cancer. 
Author Year 
Post-operative 
Chemotherapy 
Country 
With Palliative 
Gastrectomy 
Without 
Palliative 
Gastrectomy 
N 
MST 
(months) 
N 
MST 
(months) 
Shridhar, R., et al. 
15
 2013 NA USA 957 10
 
 3069
 
 7
 
 
Chang, Y., et al. 
16
 2012 + 
South 
Korea 
108 12.7 57 11.2 
Kulig, P., et al. 
13
 2012 +/- Poland 415 10.6 536 4.4 
Shimura, T., et al. 
14
 2009 + Japan 15 9.3
 a
 11 11.1
 a
 
Kubo, N., et al. 
11
 2013 + Japan 146 13.2 NA NA 
Ko, K., et al. 
17
 2012 +/- 
South 
Korea 
43 11.2 NA NA 
Syrios, J., et al. 
18
 2012 + Greece 218 13.25 NA NA 
Tanizawa, Y., et al.
19
 2011 NA Japan 18 7.5 NA NA 
Chikara, K., et al. 
12
 2008 + Japan 164 9 NA NA 
Saidi, R., et al. 
20
 2006 +/- USA 17 11.2 NA NA 
MST - Median Survival Time. NA – Result Not Available. 
+ All patients received post-operative chemotherapy; - No patients had post-operative chemotherapy: +/- A variable 
percentage of patients had post-operative chemotherapy. 
a
 Original article values were in days (respectively 284 and 337 days) and were converted to months for comparison 
purposes. 
 
Survival benefit according to metastasis location 
Peritoneal metastasis 
Eight studies reported survival outcomes after palliative gastrectomy in patients with 
peritoneal metastasis. Four of these compared MST between palliative gastrectomy and non-
resection patients (Table 2): two studies
13,16
 found a statistically significant survival benefit 
for palliative gastrectomy. However, one of them
16
 limited this benefit to patients with less 
advanced peritoneal disease (less than P3).  
One study
21
 found a significant survival benefit in 1-year, 2-year and 5-year survival 
rates with both palliative gastrectomy and with palliative chemotherapy while another, when 
examining 5-year survival rates found a higher rate for those undergoing palliative 
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gastrectomy (4.43% vs 0%, P<0.001)
22
. Finally, two studies studied the benefits of palliative 
gastrectomy associated with post-operative chemotherapy, reporting an improvement of MST 
from 8.8 months to 19 months when palliative gastrectomy was associated with S-1 
chemotherapy (without liver metastasis and non-P3 patients)
23
 and a median overall survival 
of 15.6 months when palliative gastrectomy was associated with CAPD (continuous 
ambulatory  peritoneal  dialysis) with irinotecan
24
.   
Table 2. Survival in patients with peritoneal metastasis undergoing palliative gastrectomy 
Author Year Country 
With Palliative 
Gastrectomy 
Without Palliative 
Gastrectomy Statistical 
significance 
(p) N 
MST 
(months) 
N 
MST  
(months) 
Tokunaga, M., et al. 
25
 
2012 Japan 82 13.1 66 12 0.410 
Chen, S., et al. 
26
 2012 China 168 7.2 158 6.25 >0.05 
Kulig, P., et al. 
13
 2012 Poland 142 9.8 174 4 <0.001 
Chang, Y., et al. 
16
 2012 
South 
Korea 
96
 a
 12.8
 a
 48
 a
 11.1
 a
 0.043
 a
 
10
 b
 8.6
 b
 7
 b
 9.7
 b
 0.167
 b
 
MST – Median Survival Time. 
a Data referring to P0 , P1 and P2 patients. 
b Data referring to P3 and P4 patients. 
 
Liver metastasis 
Seven studies reported survival outcomes after palliative gastrectomy in patients with 
liver metastasis. Five of these presented MST (Table 3): four 
13,16,27,28
 found a statistically 
significant benefit with palliative gastrectomy in these patients while one did not find this 
benefit
29
. One of the former
28
 also reported this benefit in the 1-year, 2-year and 3-year 
survival rates. On the other hand one of the studies                                                                                                                                                                                                                            
21
 found this benefit only in the 1-year survival rate, being palliative gastrectomy (53.9%) 
statistically superior (p=0.000) to the palliative surgery with no resection (25.6%). It should 
be noted that one of the studies
27
 supporting a survival benefit with palliative gastrectomy in 
patients in liver metastasis demonstrated this benefit regardless of the type of hepatic 
involvement: multiple liver metastasis (p=0.001), bilobar liver metastasis (p= 0.04) and liver 
metastasis with peritoneal dissemination (0.02). The same study also investigated the 
potential effect of primary tumor resection on metastatic progression-free survival which was, 
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however, not significant in a multivariate analysis (p=0.07). However, progression of these 
metastases was observed later in the resection group (7.2 versus 3.1 months). Finally, one 
publication investigating the benefits of hepatic arterial infusion (HAI)
30
 reported that HAI 
treatment had no impact in the survival rate and that the reduced overall survival in the non-
HAI group was in fact due to patients not undergoing palliative gastrectomy.  
MST – Median Survival Time. 
a Original article values were in days (respectively 422±50 and 170±16  days) and were converted to months for comparison 
purposes. 
 
Prognostic factors in patients submitted to palliative gastrectomy 
In patients undergoing palliative gastrectomy several prognostic factors have been 
reported. The one with most research was post-operative chemotherapy, being that 
chemotherapy after palliative gastrectomy was reported with increased survival.
12,16,17,20,28,30,31
 
Among other prognostic factors identified, higher DNA index
18
 , higher S-Pan 
levels
11
,  more perioperative transfusions
11
, lower performance status
18
 and undifferentiated 
histological type
12
 were correlated with shorter survival after palliative gastrectomy. High 
NLR (neutrophil-to-lymphocyte ratio)
32
, lower CA19-9 level
32
 and lower mGPS (modified 
Glasgow prognostic score)
33
  were predictors of longer survival. While one publication 
concluded that the number of non-curative factors
12
  and another
26
 that the tumor location 
were prognostic factors; a different study
13
 concluded neither of those variables influenced 
long-term outcomes.  
Table 3. Survival in patients with liver metastasis undergoing palliative gastrectomy 
Author Year Country 
With Palliative 
Gastrectomy 
Without 
Palliative0020Gast
rectomy 
Statistical 
significance 
(p) 
N 
MST 
(months) 
N 
MST 
(months) 
Tiberio, G., et al. 
28
 2015 Italy 98 6.6 44 3 0.009 
Kulig, P., et al. 
13
 2012 Poland 82 9.4 90 4.3 <0.001 
Chang, Y., et al. 
16
 2012 
South 
Korea 
15 15 10 3.1 <0.001 
Turanli, S., et al. 
27
 2010 India 18 13.9±1.6
a
 44 5.6±0.5
a
 0.0001 
Yuichiro Miki, et al. 
29
 
2012 
Japan 
 
13 10.5 12 8.7 0.5 
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Symptom relief with palliative gastrectomy 
While it is expected that patients’ symptoms will improve after palliative gastrectomy, 
only one of the identified studies
11
 demonstrated a significant positive impact of palliative 
gastrectomy in patients’ symptoms. 
 
Effects of palliative gastrectomy on Quality of Life (QoL) 
It is not easy to evaluate QoL, especially in vulnerable populations such as stage IV 
cancer patients. For this reason, only one paper
13
 presented true QoL outcomes using 
validated QoL measuring methods in stage IV gastric cancer patients undergoing palliative 
gastrectomy. It revealed a minor decrease in QoL but this did not reach statistical significance 
due to marked intersubject variability. However, different studies used different parameters as 
a surrogate marker for QoL (Table 4), including hospital-free-survival (HFS), median hospital 
stay (MHS), median oral intake and time to decrease in oral intake (defined as the time to total 
parenteral nutrition or tube feeding being required). Two studies compared some of these 
outcomes between resection and non-resection patient groups, one
27
 finding a statistically 
significant  benefit with non-resection in MHS but other two
14,16
 not confirming this evidence. 
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Table 4. QoL parameters of patients undergoing palliative gastrectomy or other interventions 
Author Year Country 
Parameter 
used 
With 
Palliative 
gastrectomy 
Without 
Palliative 
gastrectomy 
Statistical 
significance 
(p) 
Turanli, S., 
et al. 
27
 
2010 India MHS 12 8 0.0002 
Chang, Y., et 
al. 
16
 
2012 
South 
Korea 
MHS 33.5 26.0 0.465 
HFS
 a
 86.1% 84.2% 0.817 
Shimura, T., 
et al. 
14
 
2009 Japan 
MHS
 b
 24.6% 23.7% NS 
Median Oral 
Intake 
93.1% 93.2% NS 
Ko, K., et al. 
17
 
2012 
South 
Korea 
MHS 15.9 NA NA 
HFS 8.6 months NA NA 
Tanizawa, 
Y., et al. 
19
 
2011 Japan 
Time to 
decrease in 
oral take 
5.5 months NA NA 
HFS - hospital-free-survival a In this study HFS was reported as percentage of patients with no hospital visits nor readmission 
within 3 months of discharge. 
MHS - median hospital stay (days); b In this study MHS was reported as percentage of the survival time period during which 
the patient was hospitalized.  
NA – Not available . NS – Not significant. 
 
 
 
Postoperative morbidity and mortality 
Five studies
11-13,16,28
 reported detailed post-operative morbidity and mortality rates in 
patients undergoing palliative gastrectomy (Table 5), ranging between 13-23.9% and 0-4.1% 
respectively. Three of them
14,15,28
 reported these parameters in patients with or without 
palliative gastrectomy, with a higher post-operative morbidity rate in the former and a higher 
post-operative mortality rate in the latter being found in all of them.  
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Table 5. Post-operative morbidity and mortality in stage IV gastric cancer patients undergoing 
palliative gastrectomy or other interventions 
Author Year Country 
Post-Operative Morbidity Post-Operative Mortality 
With 
Palliative 
gastrectomy 
(%) 
Without 
Palliative 
gastrectomy 
(%) 
With 
Palliative 
gastrectomy 
(%) 
Without 
Palliative 
gastrectomy 
(%) 
Tiberio, G., et al. 
28
 2015 Italy 18.4 15.9 2.1 15.9 
Chang, Y., et al. 
16
 2012 
South 
Korea 
13 3.5 0 3.5 
Kulig, P., et al. 
13
 
 
 
2012 Poland 33 21 4 10 
Kubo, N., et al. 
11
 2013 Japan 23.9 NA 2.7 NA 
Chikara K., et al. 
12
 
 
2008 
 
Japan 
 
15.2 NA 4.1 NA 
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Discussion 
This systematic review investigated the role of palliative gastrectomy exclusively in 
stage IV (M1) gastric cancer patients. Two main obstacles were found in retrieving studies for 
this investigation. First, a great number of studies describe their patients as “advanced” but a 
thorough examination of their methods would often reveal that not only M1 patients were 
included in this broad definition but also locally advanced cancer patients, even though the 
current AJCC classification clearly separates one group from the other. Second, too often the 
original intent of the procedure being investigated was not clearly mentioned. Palliation 
implies the existence of significant symptoms and most importantly that the intervention is 
directed at their relief. This should define a procedure as palliative and not simply the 
incurability of the disease itself. This also implies that endpoints such as specific symptoms 
relief and quality of life should be the focus of such publications rather than survival 
endpoints. However this does not imply the intervention (gastric resection) itself cannot 
prolong the patient’s survival. In fact, different studies have investigated the benefits of the 
procedure with a non-curative reduction intent and a survival benefit was reported in most of 
them.
6,34,35
 Theoretically, if a significant proportion of the tumor load is removed, the 
remaining cancer cells might be more sensitive to the post-operative chemotherapeutic 
regimen. Besides, this reduction could relieve the metabolic demands on the patient and have 
an immunologic benefit since cancer cells release some types of immunosuppressive 
cytokines.
32
 The varied and heterogeneous definitions of palliative across the different 
publications, with the terms palliative and non-curative being frequently used 
interchangeably, have complicated the selection and interpretation of the available 
investigations. A systematic review investigating the same subject concluded gastrectomy 
was truly palliative in 48% of the stage IV gastric cancer patients in whom it was performed.
36
 
In most studies (including those where no specific metastatic position, peritoneal 
metastasis and liver metastasis were investigated), a significant benefit in survival (reported 
mainly through MST) was observed. However, some studies failed to show this benefit to be 
statistically significant. These observations are similar to the ones found in other reviews on 
the subject.
37-39
 
A significant percentage of patients had post-operative chemotherapy and in most 
studies, this was reported as positively impacting survival. As mentioned above the reduction 
in tumor volume/burden by the surgical procedure itself potentially renders the disease more 
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responsive to chemotherapy. It should be also noted that there have been recent major 
advances in chemotherapy options for gastric cancer patients, including the introduction of S-
1 plus cisplatin protocols. A recent study has reported a MST of 13 months in patients with 
advanced gastric cancer treated with this regimen.
40
 However, chemotherapy is not as 
effective as local therapies in managing symptoms caused by the primary tumor.
15
 
Only one study
11
 across the selected publications clearly reported an improvement in 
patients’ symptoms with palliative gastrectomy, while the remaining did not evaluate the 
impact of the different interventions on the patient’s symptoms. Other publications showed an 
important benefit in symptom palliation with palliative gastrectomy, namely less vomiting
41,42
 
and less hematemesis/melena
42
. Several studies have investigated different interventions for 
palliating gastric outlet obstruction (GOO): some report no significant difference between   
palliative gastrectomy and non-resection procedures
14,31
 while others observed a faster time to 
oral intake with endoscopic stenting
43,44
 but a longer symptom free survival with palliative 
gastrectomy
41
. On the other hand, one study
45
 investigating the symptom relief benefit of 
palliative radiotherapy observed an important control rate of bleeding, dysphagia/obstruction 
and pain symptoms, without additional interventions. Another study reported that patients 
who undergo surgical exploration without resection derive no survival benefit from the 
procedure, even with the performance of a gastric bypass.
41
  
The same paucity of evidence was encountered when investigating the potential 
impact of palliative gastrectomy on QOL, with only one publication
13
 presenting true QoL 
outcomes, using the Questionnaire QLQ-C30 from the European Organization for Research 
and Treatment of Cancer Care (EORTC) in which the authors (even though there was marked 
intersubject variability in this parameter) concluded that there was a significantly better 
survival compared to non-resection surgery without impairing quality of life. Nonetheless, 
validated QoL measuring methods already exist. These include the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire STO22 (EORTC 
QOLSO22) and the Functional Assessment of Cancer Therapy-Gastric Quality of Life 
Instrument (FACgc), validated in 2001 and 2011 respectively. 
39
  Mahar et al.
39
, when 
performing a systematic review on QoL outcomes of the then existing literature, found the 
same paucity of evidence, with no articles using validated QOL measuring instruments. 
Parameters such as hospital-free-survival, median hospital stay and median oral intake were 
used as surrogates for QoL in some studies. When comparing these parameters between 
palliative gastrectomy and non-resected patients, only one study
27
 found a statistically 
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significant difference between the two groups, with a longer MHS with palliative 
gastrectomy.  
One of the main arguments being used against the practice of palliative gastrectomy 
was that the increased risk of post-operative mortality would outweigh any potential benefit. 
However, the post-operative mortality is reportedly higher in the non-resection patient groups 
when compared to palliative gastrectomy. Besides, the literature has shown a decrease in post-
operative mortality related to palliative gastrectomy between the decades of 1960’s-1970’s 
and 1990’s.13,42,46 This reduction could be explained by advances in technology, surgical 
equipment, anesthesia, postoperative care, preoperative nutrition, comorbidities treatment and 
patient selection.
42
 There was however, a higher post-operative morbidity in patients 
undergoing palliative gastrectomy (with unreported statistical significance), especially when 
the procedure was performed for the urgent relief of symptoms.
19
 
One important limitation in the publications selected for this review was the fact that 
all were retrospective studies. In fact no randomized trials comparing palliative gastrectomy 
with other treatment modalities in stage IV gastric cancer patients have been published so far. 
The retrospective nature of the data available has several implications, namely the inclusion 
of patients treated over long spans of time (during which the available treatments, equipments 
and experience could have changed), variability between patients’ groups and, most 
importantly, a selection bias. Since in most papers no information is available about which 
criteria were used by the surgeons in selecting which patients to perform palliative 
gastrectomy, it is likely that the patients treated with non-resection interventions had a more 
advanced disease and/or more co morbidities which could prevent them from resection 
surgery. This could partially explain the survival and post-operative mortality differences 
between resection and non-resection patient groups. It is exactly because of this potential 
selection bias that randomized trials are required to obtain a definite answer on the subject. 
Two randomized trials are currently in development. One (KGCA01/JCOG0705 or 
REGATTA trial) will compare gastrectomy plus chemotherapy with chemotherapy alone in 
advanced gastric cancer patients in Japan and South Korea.
36
 A prospective randomized trial 
started by the National Cancer Institute in the United States (the GYMSSA trial)  will 
compare gastrectomy and/or metastasectomy plus systemic therapy versus systemic therapy 
alone.
47
 In both trials the overall survival is the main end point, but only in the latter an 
analysis of QoL is included.   
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Conclusion 
Currently there are many publications about the potential benefits of palliative 
gastrectomy in advanced gastric cancer patients. Since the existing literature has many 
limitations, it is hard to propose a clinical guidance. Even though palliative gastrectomy 
seems to have a significant benefit in survival, it cannot be recommended without weighting 
its potential risks and costs. More importantly, most of these patients eventually succumb to 
their illness and therefore a thorough evaluation of the benefit of this procedure in QoL and 
symptom relief is of the utmost importance.  
In conclusion, better designed retrospective studies and the results of future 
randomized trials are needed in order for the decision to perform a palliative gastrectomy to 
be actually based on actual evidence rather than only the surgeon’s experience or clinical 
judgment.  
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